Factor XI inhibitors: cardiovascular perspectives.

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Current anticoagulants effectively prevent thrombosis but carry significant bleeding risks.
• Factor XI deficiency suggests factor XI is crucial for thrombosis but less so for hemostasis, indicating therapeutic potential.
• Factor XI inhibitors may offer safer anticoagulation compared to existing treatments.

Purpose of the Study:

• To review the rationale for developing factor XI inhibitors.
• To summarize current clinical trial data for factor XI inhibitors.
• To discuss the future implications of factor XI inhibitors in patient care.

Main Methods:

• Review of preclinical data and clinical trial results (Phase 2 and ongoing Phase 3).
• Evaluation of various factor XI inhibitor modalities: antisense oligonucleotides, monoclonal antibodies, and small molecules.
• Analysis of patient populations including those undergoing major orthopedic surgery, with end-stage kidney disease, atrial fibrillation, and acute coronary syndromes.

Main Results:

• Phase 2 trials have shown promising results in various patient cohorts.
• Multiple factor XI inhibitors are progressing through clinical development.
• Early data suggest a potential for improved safety profiles regarding bleeding risk.

Conclusions:

• Factor XI inhibitors represent a novel therapeutic strategy for anticoagulation.
• Ongoing Phase 3 trials are critical to confirm efficacy and safety.
• These agents hold promise for safer management of thrombotic disorders.